Læknablaðið - 15.03.2011, Side 24

FRÆÐIGREINAR
Y F I R L I T
21. Bennett Berkeley L, Garofalo Roberto P, Cron Stanley G, et
al. Immunopathogenesis of Respiratory Syncytial Virus
Bronchiolitis. J Infect Dis 2007; 195:1532-40.
22. Blount RE, Jr., Morris JA, Savage RE. Recovery of
cytopathogenic agent from chimpanzees with coryza. Proc
Soc Exp Biol Med 1956; 92: 544-9.
23. van den Hoogen BG, de Jong J, Groen J, et al. A newly
discovered human pneumovirus isolated from young
children with respiratory tract disease. Nat Med 2001; 7:
719-24.
24. Richard N, Komurian-Pradel F, Javouhey E, etal. The Impact
of Dual Viral Infection in Infants Admitted to a Pediatric
Intensive Care Unit Associated with Severe Bronchiolitis.
Pediatr Infect Dis J 2008; 27: 213-7.
25. Aheme W, Bird T, Court SD, Gardner PS, McQuillin J.
Pathological changes in virus infections of the lower
respiratory tract in children. J Clin Pathol 1970; 23: 7-18.
26. Wong JYW, Rutman A, O'Callaghan C. Recovery of the
ciliated epithelium following acute bronchiolitis in infancy.
Thorax 2005; 60: 582-7.
27. Gern JE, Busse W W. The role of viral infections in the natural
history of asthma. J Allergy Clin Immunol 2000; 106: 201-
12.
28. Sheeran P, Jafri H, Carubelli C, et al. Elevated cytokine
concentrations in the nasopharyngeal and tracheal
secretions of children with respiratory syncytial vims
disease. Pediatr Infect Dis J 1999; 18:115-22.
29. Kristjansson S, Bjarnarson S, Jonsdottir I, Arnadottir T,
Wennergren G, Haraldsson A. Inflammatory responses
in respiratory syncytial virus and other viral infections in
infants: Cytokines, chemokines, and eosinopilic cationic
protein. J Allergy Clin Immunol 2003; 111 (1, Supplement
2): S343-S.
30. Somers CC, Ahmad N, Mejias A, et al. Effect of dexa-
methasone on respiratory syncytial virus-induced lung
inflammation in children: results of a randomized, placebo
controlled clinical trial. Pediatr Allergy Immunol 2009; 20:
477-85.
31. Carroll N, Cooke C, James A. The distribution of eosinophils
and lymphocytes in the large and small airways of
asthmatics. Eur Respir J 1997; 10: 292-300.
32. Everard ML, Swarbrick A, Wrightham M, et al. Analysis
of cells obtained by bronchial lavage of infants with
respiratory syncytial virus infection. Arch Dis Child 1994;
71: 428-32.
33. Eriksson M, Bennet R, Rotzén-Östlund M, Sydow M, Wirgart
BZ. Population-based rates of severe respiratory syncytial
virus infection in children with and without risk factors,
and outcome in a tertiary care setting. Acta Paediatr 2002;
91: 593-8.
34. MacDonald N, Hall C, Suffin S, Alexson C, Harris P, Mann-
ing J. Respiratory syncytial viral infection in infants with
congenital heart disease. N Engl J Med 1982; 307: 397-400.
35. Bulkow LR, Singleton RJ, Karron RA, Harrison LH. Risk
Factors for Severe Respiratory Syncytial Virus Infection
Among Alaska Native Children. Pediatr 2002; 109: 210-6.
36. Bradley JP, Bacharier LB, Bonfiglio J, et al. Severity of
Respiratory Syncytial Vims Bronchiolitis Is Affected by
Cigarette Smoke Exposure and Atopy. Pediatr 2005; 115:
e7-14.
37. Kristjánsson S, Skúladóttir H, Sturludóttir M, Wennergren
G. Increased prevalence of otitis media following
respiratory syncytial virus infection. Acta Paediatric 2010;
99: 867-70.
38. Holman RC, Shay DK, Curns AT, Lingappa JR, Anderson
LJ. Risk factors for bronchiolitis-associated deaths among
infants in the United States. Pediatr Infec Dis J 2003; 22:
483-9.
39. Murray M, Webb MS, O'Callaghan C, Swarbrick AS, Milner
AD. Respiratory status and allergy after bronchiolitis. Arch
Dis Child 1992; 67: 482-7.
40. Roosevelt G, Sheehan K, Grupp-Phelan J, Tanz RR, Lister-
nick R. Dexamethasone in bronchiolitis: a randomised
controlled trial. Lancet 1996; 348: 292-5.
41. Avner JR, Baker MD. Management of fever in infants and
children. Emerg Med Clin North Am 2002; 20: 49-67.
42. Hsiao AL, Baker MD. Fever in the new millennium: a review
of recent studies of markers of serious bacterial infection in
febrile children. Curr Opin Pediatr 2005; 17: 56-61.
43. Greenes DS, Harper MB. Low risk of bacteremia in febrile
children with recognizable viral syndromes. Pediatr Infect
Dis J 1999; 18: 258-61.
44. Unger S, Cunningham S. Effect of Oxygen Supplementation
on Length of Stay for Infants Hospitalized With Acute Viral
Bronchiolitis. Pediatr 2008; 121: 470-5.
45. Gadomski AM, Brower M. Bronchodilators for bronchiolitis.
Cochrane Database Syst Rev 2010; (12): CD001266.
46. Kristjansson S, Lödmp Carlsen KC, Wennergren G,
Strannegárd IL, Carlsen KH. Nebulised racemic adrenaline
in the treatment of acute bronchiolitis in infants and
toddlers. Arch Dis Child 1993; 69: 650-4.
47. Bentur L, Shoseyov D, Feigenbaum D, Gorichovsky Y,
Bibi H. Dexamethasone inhalations in RSV bronchiolitis:
A double-blind, placebo-controlled study. Acta Paediatr
2005; 94: 866-71.
48. Gibson PG, Saltos N, Fakes K. Acute Anti-inflammatory
Effects of Inhaled Budesonide in Asthma. A Randomized
Controlled Trial. Am J Respir Crit Care Med 2001; 163:32-6.
49. Everard M, Bara A, Kurian M, N'Diaye T, Ducharme F,
Mayowe V. Anticholinergic drugs for wheeze in children
under the age of two years. Cochrane Database Syst Rev
2005; (3): CD001279.
50. Amirav I, Luder AS, Kruger N, et al. ADouble-Blind, Placebo-
Controlled, Randomized Trial of Montelukast for Acute
Bronchiolitis. Pediatr 2008; 122: el249-55.
51. Ventre K, Randolph A. Ribavirin for respiratory syncytial
vims infection of the lower respiratory tract in infants and
young children. Cochrane Database of Systematic Reviews.
2007; (1): www.mrw.interscience.wiley.com/cochrane/
clsysrev/articles/CD000181/frame.html. 14.2.2011
52. Spurling GKP, Fonseka K, Doust J, Del Mar C. Antibiotics for
bronchiolitis in children. Cochrane Database Syst Rev 2007;
(1): CD005189.
53. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen
TP. Nebulized hypertonic saline solution for acute
bronchiolitis in infants. Cochrane Database Syst Rev 2008;
(4): CD006458.
54. Khalid A-A, Mahmoud S, Bmce LD, Rafah E1 S, Hella M,
Khalid I. Nebulized 5% or 3% Hypertonic or 0.9% Saline for
Treating Acute Bronchiolitis in Infants. J Pediatr 2010; 157:
630-4.el.
55. The IMpact-RSV Study Group. Palivizumab, a Humanized
Respiratory Syncytial Vims Monoclonal Antibody, Reduces
Hospitalization From Respiratory Syncytial Virus Infection
in High-risk Infants. Pediatr 1998; 102: 531-7.
56. Willson DF, Landrigan CP, Hom SD, Smout RJ. Com-
plications in infants hospitalized for bronchiolitis or
respiratory syncytial vims pneumonia. J Pediatr 2003; 143:
142-9.
57. Purcell K, Fergie J. Concurrent Serious Bacterial Infections in
2396 Infants and Children Hospitalized With Respiratory
Syncytial Vims Lower Respiratory Tract Infections. Arch
Pediatr Adolesc Med 2002; 156: 322-4.
58. Martinez FD. Respiratory syncytial virus bronchiolitis and
the pathogenesis of childhood asthma. Pediatr Infect Dis J
2003; 22: S76-S82.
59. McConnochie KM, D. Mark J, McBride JT, et al. Normal
pulmonary function measurements and airway reactivity
in childhood after mild bronchiolitis. J Pediatr 1985; 107:
54-8.
60. Everard ML. The relationship between respiratory syncytial
vims infections and the development of wheezing and
asthma in children. Curr Opin Allergy Clin Immunol 2006;
6: 56-61.
156 LÆKNAblaðið 2011/97